Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The platform features Healthgrades, a tool intended to connect Alzheimer's patients to experienced local clinicians.

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to invest ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...

The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for ...

Ever Palo Alto Networks Trading Pair, Alongside New Pharma Trades NEW YORK, NY / ACCESS Newswire / March 26, 2025 /Direxion, ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...